PVG Asset Management Corp lessened its position in Astrazeneca PLC (NYSE:AZN) by 70.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 77,746 shares of the company’s stock after selling 186,929 shares during the period. PVG Asset Management Corp’s holdings in Astrazeneca PLC were worth $2,650,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in AZN. Bank of New York Mellon Corp grew its holdings in Astrazeneca PLC by 14.5% in the 1st quarter. Bank of New York Mellon Corp now owns 184,654 shares of the company’s stock worth $5,749,000 after acquiring an additional 23,359 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Astrazeneca PLC by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 19,963 shares of the company’s stock valued at $622,000 after purchasing an additional 993 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Astrazeneca PLC by 19.1% during the 1st quarter. Teachers Advisors LLC now owns 937,314 shares of the company’s stock valued at $29,188,000 after purchasing an additional 150,135 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Astrazeneca PLC by 55.2% during the 1st quarter. TIAA CREF Investment Management LLC now owns 836,928 shares of the company’s stock valued at $26,062,000 after purchasing an additional 297,561 shares in the last quarter. Finally, Mackenzie Financial Corp bought a new stake in shares of Astrazeneca PLC during the 1st quarter valued at about $220,000. 14.17% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Astrazeneca PLC (AZN) Holdings Cut by PVG Asset Management Corp” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/08/astrazeneca-plc-azn-holdings-cut-by-pvg-asset-management-corp.html.

Shares of Astrazeneca PLC (AZN) traded up 0.09% during mid-day trading on Friday, reaching $34.26. 2,973,636 shares of the company traded hands. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The firm has a market capitalization of $86.75 billion, a price-to-earnings ratio of 22.47 and a beta of 0.76. The firm has a 50-day moving average price of $31.89 and a 200 day moving average price of $32.14.

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.46. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business’s quarterly revenue was down 9.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.83 EPS. On average, analysts anticipate that Astrazeneca PLC will post $1.91 earnings per share for the current year.

The company also recently announced a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were issued a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio (DPR) is 44.92%.

A number of equities research analysts have recently weighed in on the stock. BidaskClub lowered shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Liberum Capital lowered shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. BNP Paribas raised shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th. Pareto Securities raised shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, Investec raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $34.35.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.